<VariationArchive VariationID="203815" VariationName="NM_172250.3(MMAA):c.593_596del (p.Thr198fs)" VariationType="Deletion" Accession="VCV000203815" Version="30" RecordType="classified" NumberOfSubmissions="11" NumberOfSubmitters="11" DateLastUpdated="2024-07-15" DateCreated="2013-04-04" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="200054" VariationID="203815">
      <GeneList>
        <Gene Symbol="MMAA" FullName="metabolism of cobalamin associated A" GeneID="166785" HGNC_ID="HGNC:18871" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4q31.21</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="145619385" stop="145660033" display_start="145619385" display_stop="145660033" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="146540539" stop="146581186" display_start="146540539" display_stop="146581186" Strand="+" />
          </Location>
          <OMIM>607481</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_172250.3(MMAA):c.593_596del (p.Thr198fs)</Name>
      <CanonicalSPDI>NC_000004.12:145646012:TGACTGA:TGA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>4q31.21</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="145646013" stop="145646016" display_start="145646013" display_stop="145646016" variantLength="4" positionVCF="145646012" referenceAlleleVCF="ATGAC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="146567165" stop="146567168" display_start="146567165" display_stop="146567168" variantLength="4" positionVCF="146567164" referenceAlleleVCF="ATGAC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>T198fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1301" sequenceAccession="LRG_1301">
            <Expression>LRG_1301:g.51975_51978del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.146567168_146567171del" Assembly="GRCh37">
            <Expression>NC_000004.11:g.146567168_146567171del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.145646016_145646019del" Assembly="GRCh38">
            <Expression>NC_000004.12:g.145646016_145646019del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007536.2" sequenceAccession="NG_007536" sequenceVersion="2" change="g.51975_51978del">
            <Expression>NG_007536.2:g.51975_51978del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172250.3" sequenceAccession="NM_172250" sequenceVersion="3" change="c.593_596del" MANESelect="true">
            <Expression>NM_172250.3:c.593_596del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_758454.1" sequenceAccession="NP_758454" sequenceVersion="1" change="p.Thr198fs">
            <Expression>NP_758454.1:p.Thr198fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1301t1" sequenceAccession="LRG_1301t1">
            <Expression>LRG_1301t1:c.593_596del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1301p1" sequenceAccession="LRG_1301p1" change="p.Thr198fs">
            <Expression>LRG_1301p1:p.Thr198fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172250.3" sequenceAccession="NM_172250" sequenceVersion="3" change="c.593_596delCTGA" MANESelect="true">
            <Expression>NM_172250.3:c.593_596delCTGA</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172250.2" sequenceAccession="NM_172250" sequenceVersion="2" change="c.593_596delCTGA">
            <Expression>NM_172250.2:c.593_596delCTGA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA312707" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="607481.0001" DB="OMIM" />
        <XRef Type="rs" ID="796051993" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_172250.3(MMAA):c.593_596del (p.Thr198fs) AND not provided" Accession="RCV000186013" Version="12">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-02-01" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_172250.3(MMAA):c.593_596del (p.Thr198fs) AND Methylmalonic aciduria, cblA type" Accession="RCV000203312" Version="15">
        <ClassifiedConditionList TraitSetID="807">
          <ClassifiedCondition DB="MedGen" ID="C1855109">Methylmalonic aciduria, cblA type</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-03-06" SubmissionCount="7">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_172250.3(MMAA):c.593_596del (p.Thr198fs) AND Methylmalonic acidemia" Accession="RCV000780425" Version="6">
        <ClassifiedConditionList TraitSetID="9017">
          <ClassifiedCondition DB="MedGen" ID="C0268583">Methylmalonic acidemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2018-12-03" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-03-06" NumberOfSubmissions="11" NumberOfSubmitters="11" DateCreated="2013-04-04" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12438653</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15523652</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15781192</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22614770</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23026888</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28497574</ID>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301409</ID>
          <ID Source="BookShelf">NBK1231</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9017" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6374" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Isolated Methylmalonic Acidemia</ElementValue>
                <XRef ID="C537358" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Methylmalonic acidemia</ElementValue>
                <XRef ID="Methylmalonic+acidemia/4713" DB="Genetic Alliance" />
                <XRef ID="HP:0002912" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0002012" DB="MONDO" />
                <XRef ID="42393006" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MMA</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7033" />
                <XRef ID="7033" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mut– enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included: Infantile/non-B12-responsive form (mut0 enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B12-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy. Partially deficient or B12-responsive phenotypes (mut– enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation. Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures. In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.</Attribute>
                <XRef ID="NBK1231" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301409</ID>
                <ID Source="BookShelf">NBK1231</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <XRef ID="C0268583" DB="MedGen" />
              <XRef ID="C537358" DB="MeSH" />
              <XRef ID="MONDO:0002012" DB="MONDO" />
              <XRef Type="primary" ID="HP:0002912" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0003123" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0008295" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="807" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2777" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Methylmalonic aciduria, vitamin B12-responsive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Methylmalonic aciduria, vitamin b12-responsive, due to defect in synthesis of adenosylcobalamin, cbla complementation type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MMA cbl A type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Methylmalonic acidemia cblA type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Methylmalonic aciduria, cblA type</ElementValue>
                <XRef ID="MONDO:0009613" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Vitamin B12-responsive methylmalonic acidemia type cblA</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mut– enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included: Infantile/non-B12-responsive form (mut0 enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B12-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy. Partially deficient or B12-responsive phenotypes (mut– enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation. Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures. In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.</Attribute>
                <XRef ID="NBK1231" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5500" />
                <XRef ID="5500" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301409</ID>
                <ID Source="BookShelf">NBK1231</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C3-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Propionic and Methylmalonic Acidemia: C3 Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="28" DB="Orphanet" />
              <XRef ID="79310" DB="Orphanet" />
              <XRef ID="C1855109" DB="MedGen" />
              <XRef ID="MONDO:0009613" DB="MONDO" />
              <XRef Type="MIM" ID="251100" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="442125" SubmissionDate="2015-07-14" DateLastUpdated="2015-07-18" DateCreated="2015-07-18">
        <ClinVarSubmissionID localKey="39401" />
        <ClinVarAccession Accession="SCV000238975" DateUpdated="2015-07-18" DateCreated="2015-07-18" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-08-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.593_596delCTGA deletion causes a frameshift starting with codon Threonine 198, changes this amino acid to a Serine residue and creates a premature Stop codon at position 6 of the new reading frame, denoted p.Thr198SerfsX6. This mutation is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. c.593_596delCTGA has been reported previously in association with methylmalonic acidemia (MMA) (Lerner-Ellis et al., 2004; aka c.592_595delACTC). The variant is found in MMAA panel(s).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.T198SfsX6</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.2:c.593_596delCTGA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="23464" SubmissionDate="2021-03-09" DateLastUpdated="2021-03-14" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="607481.0001_METHYLMALONIC ACIDURIA, cblA TYPE" title="MMAA, 4-BP DEL, 592ACTG_METHYLMALONIC ACIDURIA, cblA TYPE" />
        <ClinVarAccession Accession="SCV000023464" DateUpdated="2021-03-14" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-11-26">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a fibroblast cell line from a patient with methylmalonic aciduria of the cblA type (251100), Dobson et al. (2002) identified a homozygous 4-bp deletion (ACTG) at nucleotide 592 of the MMAA gene. The mutation resulted in a frameshift that introduced a premature stop codon. Dobson et al. (2002) also identified this mutation in heterozygous state in a second patient and in compound heterozygous state with an 8-bp insertion (607481.0002) in a third patient.</Attribute>
              <Citation>
                <ID Source="PubMed">12438653</ID>
              </Citation>
              <XRef DB="OMIM" ID="251100" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <Name>MMAA, 4-BP DEL, 592ACTG</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 592ACTG</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="607481.0001" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">METHYLMALONIC ACIDURIA, cblA TYPE</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="483208" SubmissionDate="2016-01-07" DateLastUpdated="2022-10-01" DateCreated="2016-01-16">
        <ClinVarSubmissionID localKey="NM_172250.1:c.592_595delACTG|OMIM:251100" />
        <ClinVarAccession Accession="SCV000258483" DateUpdated="2022-10-01" DateCreated="2016-01-16" Type="SCV" Version="2" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="BookShelf">NBK1231</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NP_758454.1:p.Thr198SerfsTer6</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.1:c.592_595delACTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1855109" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1794285" SubmissionDate="2019-04-24" DateLastUpdated="2019-06-02" DateCreated="2019-06-02">
        <ClinVarSubmissionID localKey="NM_172250.2:c.593_596delCTGA|MedGen:C0268583" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000917669" DateUpdated="2019-06-02" DateCreated="2019-06-02" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-03-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23026888</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15523652</ID>
          </Citation>
          <Comment>Variant summary: MMAA c.593_596delCTGA (p.Thr198SerfsX6) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 3.7e-05 in 246266 control chromosomes. This frequency is not higher than expected for a pathogenic variant in MMAA causing Methylmalonic Acidemia (3.7e-05 vs 0.0018), allowing no conclusion about variant significance. The c.593_596delCTGA variant has been reported in the literature in multiple individuals affected with Methylmalonic Acidemia, both as a homozygous and compound heterozygous allele. These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, with the most pronounced variant effect resulting in 10%-&lt;30% of normal activity (Lerner-Ellis_2004). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar without evidence for independent evaluation, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.2:c.593_596delCTGA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Methylmalonic acidemia</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0268583" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5494893</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1895378" SubmissionDate="2019-03-21" DateLastUpdated="2019-08-26" DateCreated="2019-08-26">
        <ClinVarSubmissionID localKey="92539704|MeSH:C537358" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000967584" DateUpdated="2019-08-26" DateCreated="2019-08-26" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-12-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15523652</ID>
          </Citation>
          <Comment>The p.Thr198SerfsX6 variant in MMAA has been reported in at least 5 compound het erozygous and 1 homozygous individuals with methylmalonic acidemia (Lerner-Ellis , 2004). It has also been identified in 10/129132 of European chromosomes by gno mAD (http://gnomad.broadinstitute.org). This variant is predicted to cause a fra meshift, which alters the protein?s amino acid sequence beginning at position 19 8 and leads to a premature termination codon 6 amino acids downstream. This alte ration is then predicted to lead to a truncated or absent protein. Loss of funct ion of the MMAA gene is an established disease mechanism in autosomal recessive methylmalonic acidemia. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive methylmalonic acidemia. ACMG/AMP Criteria applied: PM2_Supportive, PVS1, PM3_Very Strong.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LMM Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">24033266</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_172250.2:EXON 4</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>NM_172250.2:c.593_596delCTGA</Name>
            <Name>p.Thr198SerfsX6</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.146567168_146567171delCTGA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Methylmalonic acidemia</ElementValue>
            </Name>
            <XRef DB="MeSH" ID="C537358" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5348959</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2694790" SubmissionDate="2020-11-24" DateLastUpdated="2020-12-12" DateCreated="2020-07-04">
        <ClinVarSubmissionID localKey="NM_172250.2:c.593_596delCTGA|OMIM:251100" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001366709" DateUpdated="2020-12-12" DateCreated="2020-07-04" Type="SCV" Version="2" SubmitterName="Centre for Mendelian Genomics, University Medical Centre Ljubljana" OrgID="505952" OrganizationCategory="clinic" OrgAbbreviation="CMG-UMCL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-04-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PS1,PP4. This variant was detected in homozygous state.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.2:c.593_596delCTGA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251100" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8622351</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2867286" SubmissionDate="2020-12-28" DateLastUpdated="2021-01-02" DateCreated="2021-01-02">
        <ClinVarSubmissionID localKey="NM_172250.3:c.593_596delCTGA|Methylmalonic aciduria cblA type" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001452011" DateUpdated="2021-01-02" DateCreated="2021-01-02" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-16">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.3:c.593_596delCTGA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Methylmalonic aciduria cblA type</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8808661</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5443016" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_172250.3:c.593_596del|OMIM:251100" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002786562" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-01-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.3:c.593_596del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251100" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2395694" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="4851393|MedGen:C1855109" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001230119" DateUpdated="2024-02-14" DateCreated="2020-04-15" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15523652</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15781192</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15523652</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22614770</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28497574</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Thr198Serfs*6) in the MMAA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MMAA are known to be pathogenic (PMID: 15523652, 15781192). This variant is present in population databases (rs779859711, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with cblA-type methylmalonicaciduria (PMID: 15523652, 22614770, 28497574). This variant is also known as c.592_595del. ClinVar contains an entry for this variant (Variation ID: 203815). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.146567165_146567168del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1855109" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7843202" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_172250.3:c.593_596del|OMIM:251100" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004193085" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.3:c.593_596del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251100" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5509568" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2023-01-21">
        <ClinVarSubmissionID localKey="126213|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002821273" DateUpdated="2024-07-15" DateCreated="2023-01-21" Type="SCV" Version="11" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>MMAA: PM3:Very Strong, PVS1, PM2</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="5" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="4" alternateAllele="A" referenceAllele="ATGAC" start="146567164" stop="146567168" variantLength="5" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2023-01</SubmissionName>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="23464" TraitType="Disease" MappingType="Name" MappingValue="METHYLMALONIC ACIDURIA, cblA TYPE" MappingRef="Preferred">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1895378" TraitType="Disease" MappingType="Name" MappingValue="Methylmalonic acidemia" MappingRef="Preferred">
        <MedGen CUI="C0268583" Name="Methylmalonic acidemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7843202" TraitType="Disease" MappingType="XRef" MappingValue="251100" MappingRef="OMIM">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2395694" TraitType="Disease" MappingType="XRef" MappingValue="C1855109" MappingRef="MedGen">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2694790" TraitType="Disease" MappingType="XRef" MappingValue="251100" MappingRef="OMIM">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2867286" TraitType="Disease" MappingType="Name" MappingValue="Methylmalonic aciduria cblA type" MappingRef="Preferred">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="483208" TraitType="Disease" MappingType="XRef" MappingValue="C1855109" MappingRef="MedGen">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1794285" TraitType="Disease" MappingType="Name" MappingValue="Methylmalonic acidemia" MappingRef="Preferred">
        <MedGen CUI="C0268583" Name="Methylmalonic acidemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5509568" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="442125" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5443016" TraitType="Disease" MappingType="XRef" MappingValue="251100" MappingRef="OMIM">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

